Effect of Early Antiviral Therapy on Duration of Cough in Flu Patients

Sponsor
Renmin Hospital of Wuhan University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03618407
Collaborator
(none)
120
1
15
8

Study Details

Study Description

Brief Summary

This study mainly focused on the effect of early antiviral treatment on the duration of cough in influenza patients.investigators conducted an early investigation of patients with positive influenza virus and asked whether patients used antiviral drugs in the early stages. According to the use of drugs, patients were divided into oral oseltamivir group, oral lotus phlegm group and other groups, and investigators will collected Inspection information and medication status,during the treatment period of patients.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Cough is a common symptom of respiratory diseases and helps to clear respiratory secretions and harmful factors, but frequent severe coughing has a serious impact on the patient's work, life and social activities. Upper respiratory tract viral infection is a common cause of coughing. Many patients have a long duration of cough after suffering from flu. Cough can last for several weeks, and most often have irritating dry cough or a small amount of white mucus sputum. This type of cough is also often referred to as "subacute cough" or "post-infection cough." The mechanisms that cause this cough have not been fully elucidated, and the effect of conventional treatment is not good, and chest imaging has no obvious abnormalities. The use of large amounts of antibiotics is ineffective or ineffective. Antihistamine H1 receptor antagonists and central antitussives are often only effective or ineffective in the short term. The effects of various bronchodilators and even hormone drugs are not clear. Due to the poor efficacy of multiple treatments, patients are repeatedly subjected to various tests, which not only increases the pain but also aggravates the economic burden.

    Therefore, it is necessary to further clarify the causes and treatment measures of post-influenza cough patients.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    120 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Retrospective
    Official Title:
    Effect of Early Antiviral Therapy on Duration of Cough in Flu Patients
    Anticipated Study Start Date :
    Sep 1, 2018
    Anticipated Primary Completion Date :
    Sep 1, 2019
    Anticipated Study Completion Date :
    Dec 1, 2019

    Arms and Interventions

    Arm Intervention/Treatment
    Oral oseltamivir group

    Patients with influenza virus positive and early oral oseltamivir capsules

    Oral Lotus Capsules group

    Patients with positive influenza virus and early oral administration of lotus extract capsules

    other group

    Influenza virus positive patients who were not treated with oral lotus capsule or oseltamivir capsules early

    Outcome Measures

    Primary Outcome Measures

    1. Cough duration [6 months]

      Investigators will follow up every other week for follow-up calls or outpatients to ask about cough and medication, until the patient stops coughing, cough lasts from 1 day to 12 weeks, and cough time is greater than 12 weeks. Investigators should seriously exclude cough caused by other factors. No other factors are still included in the study, and the maximum time is no more than 6 months. If there are other factors causing cough, it will not be included in the study.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    For patients with flu-free flu, cough for at least one week.

    1. In line with the flu etiological diagnostic criteria: According to the guidelines set by the National Health and Health Committee, the diagnosis is based on etiological screening methods or confirmed methods; ages 18 to 70 years.

    2. There are no influenza complications such as acute lower respiratory tract infection, tonsillitis, sinusitis, otitis media, myocarditis, etc.

    3. It is usually healthy and there are no chronic underlying diseases such as hypertension and diabetes.

    4. Treating with cough as the main symptom, the cough lasts for at least one week and the chest radiograph is normal.

    5. Signed informed consent.

    Exclusion Criteria:
    1. Suspected flu patients who have not received the flu etiology test;

    2. There is a clear comorbid disease (combined with other sites of acute bacterial or viral infections);

    3. There is a clear cough caused by other reasons;

    4. With severe liver and kidney dysfunction;

    5. Pregnant women.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Renmin Hospital of Wuhan University Wuhan Hubei China 430060

    Sponsors and Collaborators

    • Renmin Hospital of Wuhan University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    HuKe, Director of Respiratory and Critical Care Medicine II, Renmin Hospital of Wuhan University
    ClinicalTrials.gov Identifier:
    NCT03618407
    Other Study ID Numbers:
    • HuKe
    First Posted:
    Aug 7, 2018
    Last Update Posted:
    Aug 7, 2018
    Last Verified:
    Jul 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by HuKe, Director of Respiratory and Critical Care Medicine II, Renmin Hospital of Wuhan University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 7, 2018